medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2012; 11 (1)


Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes

Abdel-Hamid NM, Nazmy MH, Abdel-Ghany MI, Nazmy WH

Idioma: Ingles.
Referencias bibliográficas: 65
Paginas: 118-127
Archivo PDF: 464.40 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107, vi.

  2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-S78.

  3. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 2004; 5: 118-25.

  4. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11: 7391-400.

  5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.

  6. Abdel-Hamid NM. Recent insights on risk factors of Hepatocellular carcinoma. World J Hepatol 2009a; 15: 3-7.

  7. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-54.

  8. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3: 8-24.

  9. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.

  10. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-107.

  11. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004; 24: 77-88.

  12. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127: S56-S61.

  13. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127: S72-S78.

  14. el-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11: 5193-8.

  15. Tazawa J, Maeda M, Nakagawa M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-5.

  16. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35: 266-9.

  17. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-9.

  18. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 513-20.

  19. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British J Cancer 1972; 26: 239-57.

  20. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-56.

  21. Shi-Yong S. Apoptosis as a novel target for cancer chemoprevention. J National Cancer Institute 2004; 96: 662-72.

  22. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54: 1024-33.

  23. Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver Int 2006; 26: 904-11.

  24. Zhao Y, Li S, Childs EE, Kuharsky DK, Yin XM. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J Biol Chem 2001; 276: 27432-40.

  25. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431: 405-6.

  26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.

  27. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-41.

  28. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.

  29. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-21.

  30. Saha BK, Sarkar A, Basak R, Chatterjee M. 1alpha, 25-Dihydroxyvitamin D3 suppresses the effect of streptozotocin- induced diabetes during chemical rat liver carcinogenesis. Cell Biol Int 2001; 25: 227-37.

  31. Van Gieson I. Van Gieson stain. In: Theory and practice of histological techniques. Churchill Livingstone Edinburgh; 1982.

  32. Chanas SA, Jiang Q, McMahon M, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 2002; 365: 405-16.

  33. Sell S, Becker FF. alpha-Fetoprotein. J Natl Cancer Inst 1978; 60: 19-26.

  34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.

  35. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096-9.

  36. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004; 101: 1009-17.

  37. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-302.

  38. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based casecontrol study among men from Montreal, Canada. Int J Cancer 2006; 118: 2105-9.

  39. Awadallah A, Issa, HA and Soliman, MS. Evaluation of Serum Chromogranin A as a Useful Tumor Marker for Diagnosis of Hepatocellular Carcinoma. J Am Sci 2011; 7: 999-1007.

  40. Bhattacharya N. A new experimental model of rat hepatocellular carcinoma. Exp Oncol 2003; 25: 55-9.

  41. Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Mol Cell Biochem 2008; 319: 51-9.

  42. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-9.

  43. Joyce-Brady M, Jean JC, Hughey RP. gamma -glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response. J Biol Chem 2001; 276: 9468-77.

  44. Yao DF, Dong ZZ, Yao DB, et al. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. Hepatobiliary Pancreat Dis Int 2004; 3: 564-70.

  45. Volkmann M, Schiff JH, Hajjar Y, et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med 2001; 79: 594-600.

  46. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006; 25: 3848-56.

  47. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32.

  48. Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis 2004; 20: 145-53.

  49. Abdel-Hamid NM. Premalignant variations in extracellular matrix composition in chemically induced hepatocellular carcinoma in rats. J Membr Biol 2009b; 230: 155-62.

  50. Mantovani A. Cancer: inflammation by remote control. Nature 2005; 435: 752-3.

  51. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.

  52. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.

  53. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.

  54. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.

  55. Tapia MA, Gonzalez-Navarrete I, Dalmases A, et al. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007; 6: 2284-92.

  56. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 2007; 28: 365-86.

  57. Singh S, Shi Q, Bailey ST, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor- negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007; 6: 1973-82.

  58. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.

  59. O’Brien RM, Granner DK. Regulation of gene expression by insulin. Biochem J 1991; 278(Pt. 3): 609-19.

  60. Brown-Borg HM, Rakoczy SG. Glutathione metabolism in long-living Ames dwarf mice. Exp Gerontol 2005; 40: 115-20.

  61. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003; 52: 506-11.

  62. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis— impact on periodontal pathology. J Dent Res 2006; 85: 15-21.

  63. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-74.

  64. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004; 53: 2404-11.

  65. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin- induced diabetic rats. Curr Eye Res 2004; 28: 251-6.




2020     |     www.medigraphic.com